Design, synthesis and molecular docking of novel N,N-dimethylbenzenesulfonamide derivatives as potential antiproliferative agents

Figures & data

Table 1. In vitro anticancer screening of the newly synthesized compounds against human breast cancer cell line (MCF-7).

Compound no.	IC50 (μM)
Doxorubicin	32.00
6	21.81
7	60.10
8	36.40
9	25.50
10	49.30
11	20.60
12	44.20
13	51.20
14	38.46
15	38.90
16	25.83
17	31.20
18	37.90
19	44.20
20	34.40

Each value is the mean of three values.

Scheme 1. Synthesis of 1,6-dihydropyridine-3-carboxylates.

Scheme 2. Formation of pyridine, thiophene and thiazole derivatives.

Scheme 3. Formation of chromene derivatives.

Scheme 4. Synthesis of acrolyl derivatives.

Figure 1. Docking validation for the re-docked ligand (magenta) compared to the co-crystallized ligand (green) in the active site of CA IX (rmsd = 0.6715 Å, S = −14.44 Kcal mol⁻¹).

Figure 2. 3D Docking of sulfonamide derivative 6 (magenta) (S = −12.92 Kcal mol⁻¹) compared to the co-crystallized ligand (green) in the active site of CA IX (hydrogen bonds are represented by red dashed lines).

Figure 3. 2D ligand interaction of sulfonamide derivative 6 with active site amino acids of CA IX.

Figure 4. 3D Docking of sulfonamide derivative 11 (magenta) (S = −11.99 Kcal mol⁻¹) compared to the co-crystallized ligand (green) in the active site of CA IX (hydrogen bonds are represented by red dashed lines).

Figure 5. 2D ligand interaction of sulfonamide derivative 11 with active site amino acids of CA IX.